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ABSTRACT
Ponatinib, a pan-BCR-ABL tyrosine kinase inhibitor for the
treatment of chronic myeloid leukemia (CML), causes severe
side effects including vascular occlusions, pancreatitis, and
liver toxicity, although the underlying mechanisms remain un-
clear. Modifications of critical proteins through reactive metab-
olites are thought to be responsible for a number of adverse
drug reactions. In vitro metabolite screening of ponatinib with
human liver microsomes and glutathione revealed unambiguous
signals of ponatinib-glutathione (P-GSH) adducts. Further pro-
filing of human cytochrome P450 (P450) indicated that CYP1A1
was the predominant P450 enzyme driving this reaction. P-GSH
conjugate formation paralleled the disappearance of hydroxyl-
ated ponatinib metabolites, suggesting the initial reaction
was epoxide generation. Mouse glutathione S-transferase p1
(mGstp1) further enhanced P-GSH adduct formation in vitro.
Ponatinib pharmacokinetics were determined in vivo in wild-type
(WT) mice and mice humanized for CYP1A1/2 and treated
with the CYP1A1 inducers 2,3,7,8-tetrachlorodibenzodioxin
or 3-methylcholanthrene. Ponatinib exposure was significantly
decreased in treated mice compared with controls (7.7- and
2.2-fold for WT and humanized CYP1A1/2, respectively). In-
terestingly, the P-GSH conjugate was only found in the feces of
CYP1A1-induced mice, but not in control animals. Protein
adducts were also identified by liquid chromatography–tandem
mass spectrometry analysis of mGstp1 tryptic digests. These
results indicate that not only could CYP1A1 be involved in
ponatinib disposition, which has not been previously reported,
but also that electrophilic intermediates resulting from CYP1A1
metabolism in normal tissues may contribute to ponatinib
toxicity. These data are consistent with a recent report that
CML patients who smoke are at greater risk of disease progres-
sion and premature death.
Introduction
Ponatinib (Iclusig) is an orally available pan-BCR-ABL tyro-
sine kinase inhibitor that has been approved for treatment of
resistant chronic myeloid leukemia (CML) and Philadelphia
chromosome-positive acute lymphoblastic leukemia (Zhou et al.,
2011; Cortes et al., 2012; Razzak, 2013; Miller et al., 2014).
Ponatinib was structurally designedwith a carbon-carbon triple-
bond linkage to target the T315I mutation (BCR-ABLT315I),
which confers resistance to other approved tyrosine kinase
inhibitors (O’Hare et al., 2009; Huang et al., 2010). Ponatinib
has high efficacy against multiple resistant forms, including
T315Imutation in a phase I clinical trial of ponatinib in refractory
Philadelphia chromosome-positive acute lymphoblastic leukemia
(Cortes et al., 2012) and T315I tyrosine kinase inhibitor–resistant
CML cells (O’Hare et al., 2009). However, serious side effects
have been reported; thrombocytopenia (in 37% of patients)
and neutropenia (19%) are themost commonhematologic events
of ponatinib treatment (Cortes et al., 2012). Hepatotoxicity has
also been reported, including alanine aminotransferase and as-
partate aminotransferase elevation in patients in clinical trials
(10.5% and 8.2%, respectively). Cardiovascular toxicity, includ-
ing both arterial and venous thromboembolism and severe
systemic hypertension, and dose-limiting toxic effects limit its
broad application in clinic (Frankfurt and Licht, 2013; ARIAD
Pharmaceuticals, Cambridge, MA, 2014 Iclusig package insert).
However, the mechanism of ponatinib toxicity remains unclear.
The metabolic profile of ponatinib has been evaluated in
preclinical studies. The disposition of ponatinib is a result of
both esterase/amidase activity to an inactive carboxylic acid
(AP24600) and metabolism by the cytochrome P450 (P450)–
dependent monooxygenase system [ARIAD Pharmaceuticals,
2013 Iclusig (ponatinib) tablets for oral use: prescribing infor-
mation (http://wwwaccessdatafdagov/drugsatfda_docs/label/
2013/203469s007s008lblpdf); Narasimhan et al., 2013]. Pona-
tinib ismetabolized by P450CYP3A4 (and to a lesser extent by
CYP3A5, CYP2C8, and CYP2D6) toN-oxide andN-desmethyl
metabolites, the latter being 4-fold less potent than ponatinib.
Although the hydrolysis of ponatinib has been reported to be
the major pathway of disposition, a recent study showed that
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concurrent therapy with ponatinib and ketoconazole (a CYP3A4
inhibitor) significantly increased the ponatinib area under the
curve (AUC) AUC0–‘ and AUC0–t values and the Cmax values
(Narasimhan et al., 2013).
Levels of drug exposure, as well as the generation of
chemically reactive metabolites, can play a major role in drug
side effects (Baillie, 2006; Kalgutkar and Dalvie, 2015). To
investigate this possibility, we carried out a detailed analysis
of ponatinib metabolism in a panel of purified recombinant
human P450 enzymes. In addition to identifying CYP3A4 as a
major pathway of ponatinib disposition (Narasimhan et al.,
2013), we have also found that CYP1A1, an inducible enzyme
in tissues such as lung and lung tumors, is highly active
toward this compound. Intriguingly, metabolism by CYP1A1
resulted in the formation of an electrophilic metabolite, which
formed a glutathione (GSH) conjugate in a reaction catalyzed
by the glutathione S-transferases (GSTs). The significance of
these data in relation to the efficacy and side effects of ponatinib
is discussed.
Materials and Methods
Chemicals and Reagents. All reagents, unless otherwise stated,
were purchased from Sigma-Aldrich (Poole, United Kingdom).
NADPH was obtained from Melford Laboratories (Ipswich, United
Kingdom), ponatinib was purchased from LC Laboratories (Woburn,
MA), and 2,3,7,8-tetrachlorodibenzodioxin (TCDD) was purchased
from Toronto Research Chemicals (Toronto, Canada). The Nanosep
centrifugal device with Omega ultrafiltration membrane molecular
weight cutoff of 10 kDa was obtained from Pall Corporation (East
Hills, NY).
Animal Lines and Husbandry. The generation and character-
ization of hCYP1A1/1A2 mice will be described elsewhere (manuscript
in preparation). All animals were maintained under standard animal
house conditions, with free access to food (RM1 diet; Special Diet
Services, Essex, United Kingdom) and water, and a 12-hour light/12-
hour dark cycle. All animal work was carried in accordance with the
Animal Scientific Procedures Act (1986), as amended by European
Union Directive 2010/63/EU, and after local ethical review.
Subcellular Fractionation. Livers were harvested, excised, and
snap frozen in liquid nitrogen for storage at 280°C until processing.
Briefly, a small piece (∼200 mg) in three volumes of KCl-phosphate
buffer (10 mM KHPO4, 20 mM EDTA, and 150 mM KCl, pH 7.4) was
homogenized (POLYTRON PT 2100; Kinematica, Lucerne, Switzer-
land). The homogenate was centrifuged for 80 minutes at 100,000g
(30,000 rpm in an F50L rotor) at 4°C. After removal of the fatty layer,
the resultant supernatant was centrifuged for 1 hour at 100,000g
(30,000 rpm in an F50L rotor; Thermo Scientific, Perth, UK). After
ultracentrifugation, the supernatant (cytosolic fraction) was retained
and the pellet (microsomal fraction) was resuspended in KCl buffer
containing 0.25 M sucrose. The protein content of the microsomal and
cytosolic fractions was quantified by bicinchoninic acid assay (Thermo
Scientific).
Glutathione-Affinity Chromatography. The recombinantmouse
glutathione S-transferase p1 (mGstp1) and GST mixture from liver
cytosol (mouse and human) were purified using a GSTrap FF affinity
column (1ml; AmershamBiosciences AB,Uppsala, Sweden) according
to the manufacturer’s protocol. Briefly, the column was equilibrated
with five column volumes of binding buffer (phosphate-buffered saline,
pH 7.3). The sample was filtered through a 0.45 mm filter and loaded
onto the column at a flow rate of 1 ml/min, followed by washing with
five columns of binding buffer, and then the bound protein was eluted
by adding five column volumes of elution buffer (50 mM Tris-HCl,
10 mM reduced GSH, pH 8.0, at a flow rate of 1 ml/min). The eluted
protein was collected and analyzed by SDS-PAGE. The proteins were
concentrated and buffer exchanges were performed using a 10 kDa
Nanosep centrifugal device (previously conditioned by wetting with
0.5 ml of distilled water and followed by drying by centrifugation at
14,000g for 10minutes at 4°C) to 50mMTris-HCl, pH 7.4. The retained
protein residues were quantitatively dislodged from the membranes by
using 100 ml aliquots of 50 mMTris-HCl, pH 7.4. Protein concentration
was then quantified by a bicinchoninic acid assay using the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific, Somerset, NJ) according to
the manufacturer’s instructions.
In Vitro Metabolism. All incubations were performed at 37°C
and 300 rpm in a thermomixer. Human cDNA-expressed P450 isoen-
zymes coexpressed with human NADPH P450 oxidoreductase (see
Supplemental Fig. 1 for CYP:oxidoreductase ratio data) were carefully
thawed on ice prior to the experiment. Ponatinib (50 mM with 0.25%
dimethylsulfoxide) was mixed with human P450 isoenzymes (100 nM)
in 100 mM potassium phosphate buffer (pH 7.4) containing 3.3 mM
MgCl2 supplemented with or without GSH and a GST mixture from
mouse or human liver cytosol. After 5-minute preincubation at 37°C, the
incubation reactions were initiated by addition of a NADPH regenerat-
ing system (final concentration: 1.3 mM NADPH, 4 mM glucose-6-
phosphate, and 2 unit/ml glucose-6-phosphate dehydrogenase). After
5–120 minutes, an aliquot of 100 ml of reaction mixture was quenched
with same volume of cold acetonitrile containing 400 ng/ml of triazolam
as the internal standard. The samples were then centrifuged at 3000g
for 55 minutes at 4°C. An aliquot of the supernatant fraction was
analyzed by liquid chromatography (LC)–tandem mass spectrometry
(MS), i.e., LC-MS/MS.
In Vivo Studies. All animal work was carried out on 8- to
12-week-old male mice. 3-Methylcholanthrene (3-MC) was suspended
in corn oil at 4mg/ml for administration by intraperitoneal injection at
40 mg/kg (10 ml/g body weight) daily for 3 days for hCYP1A1/2 mice.
TCDD was suspended in corn oil at 1 mg/ml for administration by
intraperitoneal injection at 10 mg/kg (10 ml/g body weight) daily for
3 days for wild-type (WT) mice. For pharmacokinetic (PK) analyses,
ponatinib was first dissolved in 25 mM citrate buffer (pH 2.5) at a
concentration of 4 mg/ml for immediate administration by oral gavage
at a final dose of 40 mg/kg. For blood sample collection, 10 ml of whole
blood was withdrawn from the tail vein at the indicated time points.
Samples were immediately added to a tube containing heparin
solution (10 ml, 15 IU/ml), put into liquid nitrogen, and then stored
at 280°C until processing. On the day of analysis, acetonitrile (80 ml
containing 200 ng/ml triazolam) was added to thawed samples, which
were shaken for 15 minutes, centrifuged for 10 minutes at 16,000g,
and analyzed. Plasma ponatinib concentrations were determined by
an internal standard LC-multiple reactions monitoring (MRM)
method using calibration standards prepared in blank mouse plasma.
Feces were collected in Tecniplast mouse metabolic cages (Tecniplast,
Leicester, UK); mice were housed singly with free access to food and
water for up to 24 hours after administration of ponatinib dose. To
measure fecal GSH ponatinib metabolites each sample was diluted by
water (1:3 v/v) and homogenized with a mortar and pestle. An aliquot
of 0.25 g was extracted with 1 ml of 80%methanol for 30 minutes on a
vortex evaporator (Labconco, Kansas City, MO). After centrifugation
(30 minutes at 4000g), the solvent of a 800 ml aliquot of the supernatant
was removed by speed vacuum, followed by reconstitution in 500 ml
methanol and water (50/50, v/v), and analyzed by LC-MRM.
Western Immunoblotting Analyses. Liver microsomal samples
were adjusted to 1 mg/ml in LDS Lithium Dodecyl Sulfate sample
buffer (Life Technologies) and subjected to SDS-PAGE and immu-
noblotting as previously described (MacLeod et al., 2015). Primary
antibodies were used as follows: anti-CYP1A1 (1:1000; AB1258;
Millipore, Watford, United Kingdom) and Cyp1a (1:1000) (Forrester
et al., 1992). Anti-GRP78 (1:1000; ab21685; Abcam (Cambridge, UK))
was used as the loading control. Immunoreactive proteins were detected
using polyclonal goat anti-rabbit or anti-mouse horseradish peroxidase
immunoglobulins as secondary antibodies (Dako, Ely, United Kingdom)
and were visualized using Immobilon chemiluminescent substrate
(Millipore) and a Fujifilm LAS-3000 mini-imaging system (Fujifilm UK
Ltd., Bedford, United Kingdom).
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LC-MS-MRM Analysis. Analysis of in vitro incubation and
in vivo blood PK samples was carried out by ultra-performance
LC-MS/MS using theWaters Acquity UPLC (Micromass, Manchester,
United Kingdom) and Micromass Quattro Premier Mass Spectrome-
ter with electrospray ionization. The chromatography was performed
using a C18 column (Kinetex 1.7 m 100 A; 50  2.1 mm; Phenomenex,
Macclesfield, United Kingdom) at a temperature of 45°C with mobile
phases of 0.1% formic acid (A) and acetonitrile and 0.1% formic acid
(B). A gradient at a flow rate of 0.5 ml/min was run over 3 minutes as
follows: 0–0.5 minutes, 95% A; 0.5–0.75 minutes, 95%–67.5% A;
0.75–1.50 minutes, 67.5% A, 1.50–2.00 minutes, 67.5%–50% A;
2.00–2.50 minutes, 50%–5% A; and then returning to the initial
conditions for a final 0.5 minutes. The cone voltage and collision
energy were optimized for each substrate and MRM data were
acquired (Supplemental Table 1).
liquid chromatography eletcrospray ionization/multi-stage
mass spectrometry (LC-MS-MSn) Analysis. The LC-MS/MS sys-
tem consisted of a Waters Alliance 2690 high-performance LC system
(Waters, Milford, MA) and a LTQ-Orbitrap XL mass spectrometer
(Thermo Fisher Scientific) with an electrospray ionization interface.
The chromatography was performed on a XB-18 column (Kinetex 50
2.1 mm, 2.6 mm particle size; Phenomenex) at a temperature of 40°C.
Analytes were eluted from the column with 0.1% formic acid in water
(A) and 0.1% formic acid in acetonitrile (B). A gradient at a flow rate of
0.4 ml/min was run over 18 minutes as follows: 0–0.5 minutes, 95%–
80% A; 0.5–10 minutes, 80%–5% A; 10–12.5 minutes, 5% A;
12.5–14 minutes, 5%–95% A; and 14–18 minutes, 95% A. The mass
spectrometer was tuned to optimal conditions for ponatinib and was
operated in a data-independent acquisition mode, which consisted of
two scan events: a survey full scan (150–600 m/z) at a resolution of
30KOrbitrap andmulti-stagemass spectrometry (MSn) scan at an ion
trap. The product ions were generated by collision-induced dissocia-
tion mode.
Bioactivation of Ponatinib by Human Recombinant CPY1A1
in the Presence of mGstp1. To generate protein adducts of oxidative
ponatinib metabolites with mGstp1, incubations were conducted with
a reaction mixture of human recombinant CYP1A1 (100 nmol) in
Escherichia coli membrane, 10 mg/ml mGstp1, and 50 mM ponatinib
(0.5 ml 20 mM in acetonitrile) as substrate, in a final volume of 200 ml
100 mM potassium phosphate buffer (pH 7.4). The incubation was
started by the addition of a NADPH-regenerating system (final
concentration: 1.3 mM NADPH, 4 mM glucose-6-phosophate, 2 U/ml
glucose-6-phosphate dehydrogenase, and 3.3 mM potassium phos-
phate) and allowed to proceed at 37°C for 80minutes. The reactionwas
terminated by cooling on ice, and the E. coli membrane containing
human recombinant CYP1A1 was removed by ultracentrifugation at
41,000g at 4°C for 80 minutes. The supernatant was further filtered
through a Pall Nanosep 10KOMEGA (PNOD010C34) filter to remove
unbound ponatinib and its metabolites. The solvent was exchanged to
50 mM ammonium bicarbonate and further concentrated to 100 ml.
Aliquots of the solution (10 ml) were mixed with 10 ml of 4
NuPAGE lithium dodecyl sulfate loading buffer (Invitrogen, Carsbad,
CA) by incubation at 95°C for 5 minutes and then subjected to SDS-
PAGE on a NuPAGE Novex 10% Bis-Tris mini gel (Invitrogen
NP0341BOX). After electrophoresis at a constant 180V for 30minutes,
gels were stainedwith Coomassie Blue. Bands (20–25 kDa) containing
mGstp1 were cut from the gel, and after removing the Coomassie Blue
from the gel by adding 100 mM ammonium bicarbonate/acetonitrile
(1:1, v/v) and subsequently dehydrating with 100% acetonitrile, the
solvent was removed from the gel pieces under vacuum. The residue
was resuspended in 0.01 mg/ml MS grade trypsin (Promega, Madison,
WI) in 25 mM ammonium bicarbonate and incubated at 37°C over-
night. Peptides were extracted by adding buffer [1:2 (v/v) 5% formic
acid/acetonitrile] and evaporated by speed vacuum (Shevchenko et al.,
2006). Sampleswere redissolved for LC-MS/MS analysis in 20ml of 5%
acetonitrile containing 0.1% trifluoroacetic acid.
Data Analysis. In the present study, the absolute concentrations
of the metabolites in the incubation mixture could not be determined
because of the lack of authentic standards. Therefore, the relative
activity of the P450s was presented by comparing the concentration
of the metabolite in a sample with the concentration of the same
metabolite in the sample that had the highest response under the
same experimental condition (Yu et al., 2010). The relative activity of
the P450s toward metabolite formation could be calculated according
to the ratio of the metabolite concentration to that in the sample with
highest mass response. The PK parameters of in vivo data were
calculated with a simple noncompartmental model using the WinNonLin
software, version 4.1 (Pharsight (Certara, Cambridge, UK)) and are
shown with the S.D. values. The P values were calculated using an
unpaired t test; *P , 0.05, **P , 0.01, ***P , 0.001.
Results
Ponatinib Biotransformation and Formation of a
GSH Adduct by Human Recombinant P450 Enzymes.
The contribution of individual P450 enzymes to ponatinib
biotransformation was evaluated using a panel of 11 human
recombinant P450 enzymes (CYP1A1, CYP1A2, CYP1B1,
CYP2A6, CYP2B6, CYPC8, CYP2C9, CYP2C19, CYP2D6,
CYP3A4, and CYP2E1). Ponatinib was principally metabo-
lized via CYP3A4 and CYP1A1, as measured by the disap-
pearance of the parent drug (Fig. 1A). CYP3A4 had the highest
activity in the formation of both the N-desmethyl (AP24567)
and N-oxide (AP24734) metabolites (Fig. 1, B and C), with
lesser contributions from CYP2C8 and CYP2D6. It should be
noted that in the case of CYP2C8 and CYP2D6, the P450/P450
oxidoreductase ratio was considerably lower than for CYP3A4.
In the event that P450 oxidoreductase is rate limiting in these
samples, the actual rates ofmetabolism could be higher. In the
Fig. 1. Ponatinib metabolites and GSH adduct mediated by recombinant
human P450 isoforms. Recombinant human P450 isoforms were incubated
with ponatinib, and parent drug, metabolites, and conjugate determined
as described inMaterials andMethods. (A) Disappearance of ponatinib. (B)
Formation of N-demethylation (AP24567). (C) Formation of N-oxidation
(AP24734). (D) Formation of GSH adduct (P-GSH).
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case of CYP1A1, metabolism of ponatinib resulted in four
different monohydroxylated products (P-OH, m/z 549) with
retention times of 5.00minutes (P-OH-1), 5.60minutes (P-OH-2),
5.94 minutes (P-OH-3), and 7.07 minutes (P-OH-4), as well
as a number of dihydroxylated products (see Fig. 2 and
SupplementalMaterial for a more detailed description of the
metabolites formed). The major metabolites were 2- and
4-hydroxyponatinib. These metabolites were also produced,
to a lesser degree, by CYP1A2 and CYP1B1. The formation
of hydroxylated metabolites could be a consequence of epox-
idation reactions, a characteristic activity of CYP1A1. For
this reason, we also carried out incubations in the presence of
GSH. Indeed, this resulted in the formation of a ponatinib-
GSH (P-GSH) conjugate. The P-OH-2 and P-OH-4 metabolites
were not detected in incubations containing GSH, whereas
P-OH-1 andP-OH-3were unchanged (Fig. 2A,middle), suggest-
ing that epoxidation had taken place at the site of these
hydroxylation reactions. In addition, the formation of the
dihydroxylation products was significantly reduced when
GSH was added to the incubation (Fig. 2B, middle). Genera-
tion of P-GSHwas not detected with any other P450 isoforms.
The MS spectrum of P-GSH revealed a molecular ion
[M12H]21 of m/z 419.7, suggesting a GSH adduct with the
addition of the sulfhydryl nucleophile to ponatinib (Supple-
mental Fig. 2A). Fragmentation of P-GSH molecular ions
resulted in neutral loss of 75 and 129, corresponding to
elimination of the glycine and pyroglutamate of GSH, re-
spectively (Supplemental Fig. 2B), but yielded no information
on the specific site of ponatinib modification. MS analysis of
the fragments containing four monohydroxylated products
clearly indicated that CYP1A1-mediated oxidation had oc-
curred on the partial structure of ring A, linker B, or ring C,
and that GSH conjugation had occurred on ring C (Supple-
mental Figs. 3–5).
Glutathione S-Transferases Catalyze the Formation
of P-GSH Conjugates. The action of electrophiles with GSH
is catalyzed by GST (Hayes et al., 2005; Tew and Townsend,
2012). Therefore, we investigated this possibility through the
addition of recombinant GST or GST mixtures to the in-
cubation system. The formation of P-OH-2 and P-OH-4 was
linear for at least 20 minutes and with differing concentra-
tions of recombinant CYP1A1 protein up to 10 nM at 3 mM
ponatinib. Incubations were therefore routinely carried out for
20 minutes with 10 nM recombinant CYP1A1 protein. The
formation of the P-GSH conjugate was significantly increased
by the addition of recombinant mGstp1 protein up to 20 mg/ml
(Fig. 3A). The fact that this reaction was saturated at 20 mg/ml
suggests that the rate of hydroxylation was rate limiting in
Fig. 2. Reversed-phase LC selected ion chromatograms of ponatinib
oxidation and GSH adduct mediated by CYP1A1. Ponatinib (50 mM) was
incubated with CYP1A1 in the presence of an NADPH regeneration
system as described in Materials and Methods. (A) Formation of P-OH (m/z
549.22) (top) in the absence of GSH andmGstp1, and (middle) in the presence
of 5 mM GSH and 10 mg/ml mGstp1; (bottom) formation of P-GSH (m/z, 2+,
419.65) in the presence of 5 mMGSH and 10 mg/ml mGstp1. (B) Formation of
P-2OH (m/z 565.22) (top) in the absence of GSH and mGstp1 and (middle) in
the presence of 5 mM GSH and 10 mg/ml mGstp1; (bottom) Formation of
P-OH-GSH (m/z, 2+, 427.65) in the presence of 5 mM GSH and 10 mg/ml
mGstp1.
Fig. 3. Effect of GST and GSH concentrations on the formation of
monooxidation product and P-GSH. Ponatinib was incubated with CYP1A1
as described in Materials and Methods. (A) Formation of P-GSH, (B)
formation of P-OH-2, (C) formation of P-OH-4, and (D) formation P-OH-1
in the presence of GSH and recombinant mGstp1 (black circles) or bovine
serum albumin (BSA) (white square). (E) Formation of P-GSH in the
presence of GSH and recombinant mGstp1 (black bar) or BSA (white
bar). (F) Formation of P-GSH in the presence of GSH and GST fractions
from WT, Gstp1/2 NULL mice, or human liver cytosol.
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this experiment. Consistent with the data shown in Fig. 2, the
formation of P-OH-2 and P-OH-4 was inversely related to the
formation of the P-GSH conjugate (Fig. 3, B and C), whereas
the formation of P-OH-1 was not affected by the addition of
mGstp1 (Fig. 3D).
The dependence of GST-mediated P-GSH conjugate on GSH
concentration is shown in Fig. 3E. At a GSH concentration of
5 mM, the rate of the mGstp1-catalyzed P-GSH conjugate
formation was approximately double the rate of the nonenzymic
reaction. However, at a GSH concentration of 0.05 mM the
rate of the enzyme-catalyzed conjugate was increased more
than 40-fold compared with the nonenzymic control (68%
versus 1.4%, respectively). These differences were also
reflected in an inverse manner by the formation of P-OH-2
and P-OH-4 (data not shown). Therefore, the effect of mGstp1
on the rate of P-GSH-conjugated formation is greatest at the
lowest GSH concentration, consistent with a previous report
that the covalent binding rate of an acetaminophen-GSH
conjugate is greatest at low GSH concentrations (Rollins and
Buckpitt, 1979).
To further investigate the role of GSTs in the formation of
the P-GSH conjugate, Gst/GST mixtures were purified from
Gstp1WT and Gstp1/2NULL mice and human liver through a
GSTrap FF affinity column and incubated with ponatinib.
Compared with the activity of the Gst mixture from mouse
Gstp1WT liver cytosol (100%), the formation of P-GSH was
significantly reduced in both Gstp1/2NULL (56%) mice in-
dicating that, in agreement with the data obtained with the
recombinant enzyme, Gstp is responsible for ∼60% of the
murine hepatic conjugating activity. The activity of human
liverGSTswas also lower (28%), which could be ascribed to the
fact that human hepatocytes from healthy individuals do not
express glutathione S-transferase P (GSTP) (Fig. 3F).
Induction of CYP1A1 Markedly Alters Ponatinib
Exposure and Induces P-GSH Conjugate Excretion
In Vivo. To study the contribution of CYP1A1 to the
metabolism and disposition of ponatinib in vivo, WT, and
humanized hCYP1A1/1A2 mice were administered the aryl
hydrocarbon receptor activators TCDD or 3-MC for 3 days
prior to ponatinib administration. In WT mice treated with
TCDD an 87% reduction in the AUC0–8 hours value and a
significant decrease (62%) in the ponatinib half-life were
observed (Fig. 4A; Table 1). In hCYP1A1/1A2 mice treated
with 3-MC, significant reductions in both the AUC0–8 hours
(54%) and half-life (67%) values for ponatinib were also
observed (Fig. 4B; Table 1). In addition, significant amounts
of the P-GSH conjugate were detected in fecal samples from
3-MC-treated hCYP1A1/1A2 mice (Fig. 4F). This metabolite
was not detectable in control (vehicle-treated) animals treated
with ponatinib (Fig. 4E). The absolute level of the P-GSH
conjugate formed could not be determined because relevant
standards were not available.
Ponatinib Forms an Adduct with mGstp1 in the
Presence of CYP1A1. It has often been observed that the
conjugation of electrophiles by Gstp1 also results in covalent
modification of Gstp1 itself. To investigate this possibility,
tryptic peptides obtained following incubations of ponatinib
with CYP1A1 and Gstp1 were analyzed and two different
adducts of Gstp1 were identified (Supplemental Table 2).
Further MS analysis demonstrated that ponatinib-Gstp
adducts had been formed on Cys-14 and Cys-47, but not on
Cys-167.
Discussion
Ponatinib is used to treat CML patients who have relapsed
following imatinib therapy (Holyoake and Vetrie, 2017).
Although effective, the use of this drug is compromised by a
number of serious side effects including vascularitis, pancre-
atitis, and hepatotoxicity (Cortes et al., 2013; Lipton et al.,
2016). To obtain greater insights into pathways of ponatinib
metabolism and toxicity we investigated the enzymes involved
in its disposition and the metabolites produced by differ-
ent human P450 enzymes (Fig. 5). Studies were carried out
in vitro using humanized mouse models. In agreement with
the published literature, CYP3A4 was the major hepatic
P450 enzyme involved in the production of the N-desmethyl
(AP24576) and N-oxide (AP24734) metabolites (Narasimhan
et al., 2013). However, a number of different metabolites were
produced by CYP1A1. Surprisingly, this potentially important
pathway of ponatinib metabolism has, to our knowledge,
not been previously reported. The metabolites produced by
CYP1A1 were reduced by the addition of GSH to the in-
cubation medium, suggesting that reactive electrophilic prod-
ucts had been formed, probably epoxides. Epoxides can be
inactivated by a number of enzymes, including GSTs and
epoxide hydrolases (Seidegård and Ekström, 1997). In support
of epoxide formation, we have shown that the formation of the
GSH conjugate of ponatinib is greatly increased by the
addition of both murine and human GST. In particular, we
have demonstrated that Gstp has significant activity in this
regard. If an epoxide was the electrophilic intermediate, it
Fig. 4. Activation of the aryl hydrocarbon receptor alters ponatinib
pharmacokinetics and formation of GSH adduct in vivo. (A) PK profiles of
ponatinib in WT mice treated with vehicle (circles; n = 3) or TCDD
(squares; n = 3). (B) PK profiles of ponatinib in huCYP1A1/2 mice treated
with vehicle (circles; n = 3) and 3-MC (squares; n = 3). (C) Western blots of
hepatic microsomal fractions from WT mice dosed with either vehicle or
TCDD. (D)Western blots of hepatic microsomal fractions from huCYP1A1/
2 mice dosed with either vehicle or 3-MC. (E) LC-MRM chromatogram of
P-GSH in feces (up to 24 hours) from ponatinib-treated humanized
CYP1A1/2 mice. (F) LC-MRM chromatogram of P-GSH in feces (up to
24 hours) from ponatinib-treated humanized CYP1A1/2 mice pretreated
with 3-MC. Apparent PK parameters are detailed in Table 1.
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might have been anticipated that two GSH adducts would
have been formed. This may be the case, but not observed, if
the two adducts were not separated by ultra-performance LC.
Also, the MS fragmentation pattern would unfortunately not
distinguish the sites of glutathionylation. In addition, it is
feasible that one site of glutathionylation was preferred due to
steric differences, or the reaction catalyzed by Gstp generates
a site-specific product. The formation of reactive epoxides from
ponatinib and their inactivation by Gstp has a number of
possible implications. Epoxides are chemically reactive and
can react covalently with both DNA and proteins to cause
mutations and toxicity (Hinson and Roberts, 1992; Boelsterli,
1993; Swenberg et al., 2011). The nucleophilic sites in proteins
include cysteine residues, consistent with our finding here
that metabolic activation of ponatinib resulted in cysteine
conjugates of Gstp1. The cysteine residues, especially Cys-47
of human enzyme GSTP1-1, have been found to be targeted by
many electrophilic compounds resulting from P450 metabo-
lism such as acetaminophen, clozapine, and troglitazone
(Orton and Liebler, 2007; Tew, 2007; Boerma et al., 2011,
2012; Zhang et al., 2014). When ponatinib was incubated with
Gstp1 in the presence of recombinant human CYP1A1,
adducts of ponatinib were observed on Cys-14 and Cys-47.
The fact that no adducts of ponatinib to Cys-169were observed
in this study may be due to its low reactivity, or perhaps more
likely to the relative insensitivity of our methodology in
detecting Cys-169-containing tryptic peptides. It would have
been interesting to establish whether the addition of epoxide
TABLE 1
Pharmacokinetic parameters of ponatinib in WT mice and hCYP1A1/2 pre-treated with TCDD or 3-MC
The PK parameters were calculated as outlined in Materials and Methods. The P values were calculated using an
unpaired t test: *P # 0.05; **P # 0.01; ***P # 0.001.
Genotype Pretreatment t1/2 Cmax AUC0–8 hours AUC0–‘
hour mg/ml hour*mg/ml hour*mg/ml
WT Vehicle 6.2 6 0.2 1,212 6 222 7,011 6 1,490 12,620 6 2,230
WT TCDD 2.4 6 0.8** 253 6 42** 908 6 59** 1,044 6 175**
hCYP1A1/1A2 Vehicle 13.9 6 1.7 705 6 96 4,170 6 500 9,740 6 2,100
hCYP1A1/1A2 3-MC 4.6 6 0.8** 620 6 245 1,920 6 520* 3,650 6 1,890*
Fig. 5. Ponatinib structure and disposition. The structure of ponatinib is shown, along with its known metabolites and pathways of disposition. The
involvement of human P450 isoforms is also indicated.
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hydrolase to the incubation reduced the formation of the GSH
conjugate. However, we have been unable to source any
functionally active epoxide hydrolase, and while we believe
that epoxide formation is the initial oxidation step, this
remains to be formally established.
Therefore, it is possible that the formation of reactive
epoxides from ponatinib contributes to the side effects associ-
atedwith its clinical use. CYP1A1 is a highly inducible enzyme
and unlike many other P450s can be expressed inmost tissues
(Hussain et al., 2014). Metabolic activation could therefore, in
principle, occur in all of the reported ponatinib target tissues.
CYP1A1 levels are constitutively very low, but are highly
inducible on activation of the aryl hydrocarbon receptor by
compounds including polycyclic aromatic hydrocarbons found
in cigarette smoke (Schiwy et al., 2015). It is interesting to
note that hypertension or vaso-occlusive disease observed
following ponatinib administration has been associated with
smoking (Jain et al., 2015). This potential association is
therefore worthy of further epidemiologic studies. If reactive
metabolites of ponatinib are involved in its toxicity this could
be reduced using inhibitors of CYP1A1. It is worthy of note
that the reactive metabolites of ponatinib are also inactivated
by conjugation with GSH, mediated at least in part by GSTP.
GSTP is expressed in most cell types and indeed in many
tumors resistant to anticancer drugs (Henderson et al., 2011,
2014; Tew and Townsend, 2011). Therefore, cellular GSH
and GSTP status may also be an important determinant of
ponatinib side effects.
In addition to possible involvement in ponatinib side effects,
or indeed as a determinant of intratumoral drug concentra-
tion, CYP1A1 and CYP1A2 may also contribute to ponatinib
exposure since plasma levels and half-life were significantly
changed in CYP1A1/1A2 humanized mice treated with aryl
hydrocarbon receptor activators (Fig. 4). The PK parameters
obtained using this model showed comparable plasma half-life
(t1/2, 13.9 hours) to that in human (∼24 hours), whereas the t1/2
value was 6.2 hours in WT mice demonstrating the strengths
of using humanized models for such studies.
CYP1 family enzymes, especially CYP1A1 and CYP1B1,
are overexpressed in myeloblastic and lymphoid cell lines
such as U937, BALL-1, and HL-60 (Nagai et al., 2002). The
potential expression of these enzymes in CML cells may
also be a factor in drug efficacy, or indeed drug resistance.
Indeed, our findings provide a mechanistic rationale for the
recent report that CML patients that are smokers are at
increased risk of disease progression and premature death
(Lauseker et al., 2017).
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